Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation

Dat Ngo,Amanda Blackmon,Monzr M. Al Malki

DOI: https://doi.org/10.1038/s41409-024-02425-w

2024-10-09

Bone Marrow Transplantation

Abstract:Core binding factor acute myeloid leukemia (AML) defined by cytogenetic abnormalities of t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22) [referred to as t(8;21) and inv(16) respectively] is classified as favorable risk by the ELN 2022 guidelines in the context of cytarabine-based intensive chemotherapy [1]. Harboring either of these aberrations results in the formation of fusion genes, RUNX1-RUNX1T1 (or AML1/ETO) and CBFB-MYH11 respectively, that disrupt the function of core-binding factor (CBF) necessary for normal hematopoiesis [2]. Studies have shown complete remission (CR) rates of approximately 80–90% in adult CBF AML and allogeneic hematopoietic stem cell transplantation (alloHCT) is generally not recommended in first remission (CR1). Unfortunately, approximately 40–50% will eventually experience a relapse [3]. The impact of concomitant mutations with CBF AML on outcomes has been of interest to refine prognostication. In particular, the presence of KIT mutations, found in approximately 25% of CBF AML patients, have been associated with higher relapse rates [4, 5]. Marcucci et al. published their results that demonstrated that the addition of Dasatinib, a multi-kinase inhibitor with activity to KIT and SRC, to 7 + 3 and high-dose cytarabine consolidation yielded a CR rate of 90% with only a relapse rate of 16% in all patients with CBF AML [4]. In addition, the study produced 3-year disease free survival (DFS) and overall survival (OS) results of 75% and 77% respectively, with much better responses seen in younger patients with an age less than 60 years (79% and 85% for younger patients, and 60% and 51% for older patients). KIT mutation was present in 11 out of 60 patients (19%) and was only able to show benefit in younger patients only when compared to wild-type in a post-hoc analysis with a 3-yr DFS of 83% in KIT mutated compared to 77% KIT wild-type and 3-yr OS of 88% in KIT mutated compared to 84% in KIT wild-type. The authors reported that alloHCT was performed in six patients (one in CR1 and 5 with relapse), but outcomes for these patients were not described. In patients who do experience a relapse or have rising measurable residual disease (MRD) in CR1, HCT is indicated.

oncology,immunology,hematology,transplantation